Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook
04:33pm, Wednesday, 10'th Aug 2022
Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
07:33pm, Tuesday, 09'th Aug 2022
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 6% and 15.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2022 Results - Earnings Call Transcript
05:58pm, Tuesday, 09'th Aug 2022
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
11:22am, Friday, 08'th Jul 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
08:33am, Friday, 08'th Jul 2022
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
7 Biotech Stocks With Key Catalysts Coming in July
06:15am, Monday, 27'th Jun 2022
Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
01:13pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
10:24am, Tuesday, 21'st Jun 2022
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 09'th Jun 2022
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
08:30am, Wednesday, 08'th Jun 2022
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present a
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
01:40pm, Wednesday, 25'th May 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
04:15pm, Thursday, 19'th May 2022 Zacks Investment Research
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
01:35pm, Thursday, 19'th May 2022 Zacks Investment Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
